Ferring Pharmaceuticals
- OPTIMISE study found a treat-to-target (T2T) management strategy in people with mild-to-moderate ulcerative colitis (M2M UC) being treated with 5-aminosalicylic acid (5-ASA; mesalazine) utilisingfaecal calprotectin (FC) home monitoring over 12 months achieved a significantly higher rate of endoscopic and clinical remission compared to a symptom-based approach which did not utilise FC home monitoring.1
- These data support clinical thinking that T2T is the preferred management strategy for inflammatory bowel disease (IBD)2,3 and demonstrates that mesalazine therapy is an integral part of this approach in M2M UC.
/Public Release.
